Education
About Us
Working with TipRanks
Follow Us
Evgen Pharma (GB:TCF)
:TCF
TCF Stock Chart & Stats
Day’s Range― - ―
52-Week Range0.20p - 1.25p
Previous CloseN/A
Volume87.69K
Average Volume (3M)7.82M
Market Cap
£5.37M
Enterprise Value-1.77M
Total Cash (Recent Filing)£1.20M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Dec 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,148,963,600
10 Day Avg. Volume13,913,842
30 Day Avg. Volume7,818,113
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Evgen Pharma News
TCF FAQ
What was Evgen Pharma’s price range in the past 12 months?
Evgen Pharma lowest share price was 0.20p and its highest was 1.25p in the past 12 months.
What is Evgen Pharma’s market cap?
Evgen Pharma’s market cap is £5.37M.
When is Evgen Pharma’s upcoming earnings report date?
Evgen Pharma’s upcoming earnings report date is Dec 18, 2025 which is in 95 days.
How were Evgen Pharma’s earnings last quarter?
Currently, no data Available
Is Evgen Pharma overvalued?
According to Wall Street analysts Evgen Pharma’s price is currently Overvalued.
Does Evgen Pharma pay dividends?
Evgen Pharma does not currently pay dividends.
What is Evgen Pharma’s EPS estimate?
Evgen Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evgen Pharma have?
Evgen Pharma has 2,148,963,600 shares outstanding.
What happened to Evgen Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evgen Pharma?
Currently, no hedge funds are holding shares in GB:TCF
Company Description
Evgen Pharma
Evgen Pharma (TCF) is a clinical-stage drug development company focused on the development of sulforaphane-based pharmaceuticals for the treatment of multiple diseases. The company operates in the biotechnology sector, utilizing its proprietary Sulforadex technology to stabilize and enhance the bioavailability of sulforaphane, a naturally occurring compound. Evgen Pharma's core products are centered around its lead compound, SFX-01, which is being investigated for use in cancer, neurological disorders, and other health conditions.
Evgen Pharma (TCF) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Oxford BioDynamics
―
Cizzle Biotechnology Holdings PLC
―
HemoGenyx Pharmaceuticals Plc
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---